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Abstract
Background: Paired-like homeodomain 2 (PITX2) is a bicoid homeodomain transcription factor which plays an essential role
in maintaining embryonic left-right asymmetry during vertebrate embryogenesis. However, emerging evidence suggests
that the aberrant upregulation of PITX2 may be associated with tumor progression, yet the functional role that PITX2 plays
in tumorigenesis remains unknown.
Principal Findings: Using real-time quantitative RT-PCR (Q-PCR), Western blot and immunohistochemical (IHC) analyses, we
demonstrated that PITX2 was frequently overexpressed in ovarian cancer samples and cell lines. Clinicopathological
correlation showed that the upregulated PITX2 was significantly associated with high-grade (P= 0.023) and clear cell
subtype (P= 0.011) using Q-PCR and high-grade (P,0.001) ovarian cancer by IHC analysis. Functionally, enforced expression
of PITX2 could promote ovarian cancer cell proliferation, anchorage-independent growth ability, migration/invasion and
tumor growth in xenograft model mice. Moreover, enforced expression of PITX2 elevated the cell cycle regulatory proteins
such as Cyclin-D1 and C-myc. Conversely, RNAi mediated knockdown of PITX2 in PITX2-high expressing ovarian cancer cells
had the opposite effect.
Conclusion: Our findings suggest that the increased expression PITX2 is involved in ovarian cancer progression through
promoting cell growth and cell migration/invasion. Thus, targeting PITX2 may serve as a potential therapeutic modality in
the management of high-grade ovarian tumor.
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Introduction
Ovarian cancer is one of the most common cancer among the
female population in worldwide [1].The high mortality rate of
ovarian cancer is due to the late diagnosis and poor therapeutic
response because the disease is often manifested with little or non-
specific symptoms at the early stage [2,3,4]. Ovarian cancer can be
classified into four subtypes; serous, endometrioid, mucinous and
clear cell, based on the histological differentiation of ovarian
epithelium and underlying genetic alterations [3,5,6]. The grading
of ovarian tumor is categorized in accordance with International
Federation of Gynaecology and Obstetrics (FIGO) system,
revealing that high-grade tumor exhibit the characteristic of faster
cell growth and poor prognosis as well as chemoresistance
compared with low grade tumor [7,8].
Paired-like homeodomain 2 (PITX2) transcription factor is the
member of bicoid homeodomain family and plays an important role
in embryogenesis of vertebrates [9]. Several studies have reported
that mutation of PITX2 is associated with the pathogenesis of
Axenfeld-Rieger syndrome (ARS) which is an autosomal dominant
human disease characterized by developmental defects of eye, teeth
and heart [6]. Recent reports have documented that PITX2 is
overexpressed in nonfunctional pituitary adenomas [10], node-
positive colorectal cancer [11] and thyroid cancer [12]. Moreover,
inhibition of PITX2 expression by shRNA in thyroid cancer cells
significantly reduced the capacity of cell growth in soft-agar assay,
suggesting that PITX2 may have oncogenic potential and may be
involved in tumor progression [12].
In the present study, we demonstrated that PITX2 was frequently
upregulated and was significantly associated with high-grade
ovarian cancer. Using ovarian cancer cell models, we revealed that
the upregulated PITX2 could elevate cell cycle regulators such as
CyclinD1 and C-myc, and promote cell proliferation, cell migra-
tion/invasion as well as tumor growth in xenograft model mice. Our
findings provide further insight for the oncogenic role of PITX2 in
mediating ovarian cancer tumorigenesis.
Materials and Methods
Clinical samples and cell lines
Surgical resection of 97 tumor samples from primary ovarian
cancer patients and normal ovaries samples from benign disease
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were randomly chosen for Q-PCR analysis. The histological
subtype and stage of the tumors were categorized according to
International Federation of Gynaecology and Obstetrics (FIGO)
classification. Written informed consent was taken by the above
participants and the use of these clinical samples was approved by
Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster (HKU/HA HKW
IRB)(Institutional Review Board number: UW05-143 T1806).
Two immortalized human ovarian surface epithelial cells were
used: HOSE 10-2 and HOSE 17-1(kindly provided by Professor
George Tsao, The University of Hong Kong) [13]. An immor-
talized human oviductal epithelial cell line, OE-E6/E7, was
obtained from Dr. Calvin Lee (The University of Hong Kong)
[14]. Nine ovarian cancer cell lines were used: OV2008, C13*,
A2780s, A2780cp (kindly provided by Professor Benjamin Tsang,
The University of Ottawa) [13,15], OV420, OV429, OV433,
OVCAR3, SKOV-3, TOV21G, mouse fibroblast Wnt3a L cells
and Human Embryonic Kidney 293 cells (HEK 293) (America
Type Culture Collection, Rockville, MD, USA). All cell lines were
cultured in either minimum essential medium or Dulbecco’s
modified Eagle medium with 10% fetal bovine serum and 1%
Penicillin-Streptomycin in 75 cm2 flasks and incubated at 37uC in
5% CO2.
Plasmids and cell transfection
pCI-HA-PITX2A expressing plasmid (gift from Dr. Kathy
Kozlowski, University of Michigan) was used for ectopic expres-
sion of HA-tagged PITX2A. The plasmid contains full length
human PITX2AcDNA and its expression was driven by the CMV
promoter. The pCI vector was used as the negative control. The
HuSHpGFP-V-RS plasmid vector and short hairpin RNA
interference (shRNA) targeting PITX2 in pGFP-V-RS vector
(pGFP-V-RS-PITX2) were purchased from OriGene Technologies
(OriGene Technologies, Inc, Rockville, MD, USA). The shRNA
sequence targeting PITX2 was 59 GCC GTT GAA TGT CTC
TTC TCC AAA GAC TC 39.LipofectamineTM 2000 (Invitrogen
Life Technologies, Carlsbad, CA, USA) was used for cell
transfection according to the manufacturer’s instructions. Stable
cells overexpressing PITX2A or knockdown of PITX2 were
harvested after 14 days of puromycin (1 mg/ml) selection and
verified by Western blot analysis.
RNA extraction and reverse transcriptase-PCR
Total RNA from the clinical samples and the cultured cells was
isolated using the TRIzol reagent (Invitrogen). The cDNA was
prepared using Reverse transcription reagent kit (Applied Biosys-
tems, Foster City, CA, USA). The quantitative reverse transcrip-
tase-PCR (Q-PCR) used for evaluation the expressions of PITX2,
Cyclin-D1 and C-myc was performed by TaqmanH Gene expression
Assays; human PITX2 (Assay ID: Hs00165626_m1), human
Cyclin-D1 (Assay ID: Hs00765553_m1) and human C-myc (Assay
ID: Hs00153408_m1), in an ABI PRISMTM 7500 system (Applied
Biosystems). The human 18S rRNA (Assay ID: Hs99999901_m1)
was used as an internal control.
Western blot analysis
Cells were lysed by lysis buffer (Cell Signaling Technology)
containing protease inhibitor (Sigma) and Phenylmethylsulfonyl
fluoride (PMSF) (Sigma Chemical Co., St Louis, MO, USA). The
protein samples were separated by 10% SDS-PAGE and electro-
blotted onto the Hybond-P membranes (Amersham Pharmacia
Biotech, Cleveland, OH, USA). Blots were blocked with 5% skim
milk, followed by incubation with PITX2 (C16) and C-Myc (N262)
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), Cyclin-D1
and b-Catenin (Cell Signaling), Anti-HA and b-actin(Sigma)
overnight at 4uC. Blots were then incubated with anti-mouse,
anti-rabbit (Amersham Pharmacia Biotechnology) and anti-goat
(Santa Cruz) secondary antibodies conjugate with horseradish
peroxidase for 1 hour in room temperature and visualized using
ECLTM Western Blotting Detection Reagent (Amersham).
For immunohistochemical analysis, two commercial ovarian
cancer tissue arrays (OVC1021 and OVC481, Pantomics Inc, San
Francisco, CA)was immunostained with primary rabbit polyclonal
anti-PITX2 antibody (AbcamInc, Cambridge, MA, USA) in 1:200
dilution. The stained section was identified as positive or negative.
For those immuno-positive samples, the intensity of the staining
(+1, faint, +2 moderate, +3 strong and +4 very strong) and the
proportion of stained area (0–100%) were scored. The immuno-
reactivity of each sample was determined by multiplying the
intensity and percentage of stained area. The mean of immuno-
reactivity value of normal and borderline cases was used to
normalize all cases. All tissue section was examined and scored
independently by two investigators.
Cell viability assay
Cell viability was analyzed by cell proliferation kit (XTT)
(Roche Applied Science, Indianapolis, IN, USA) according to the
manufacturer’s instruction. Each sample was performed triplicate
and three independent experiments were carried out.
Soft-agar assay
A total of 16104 cells were prepared in 1.5 ml full medium
containing 0.6% agarose. The mixtures were added onto the
solidified bottom layer containing 1% agar in 2 ml full medium.
Viable colonies were counted and photographed after 14–36 days.
The experiment were performed in triplicate and carried out three
times independently.
Wound Healing assay
Cells were seeded in a six well plate until it reached full
confluence in a monolayer. Next, medium in each well was
replaced by fresh medium containing Mitomycin C (10 mg/ml)
(Sigma) and incubated for 3 hours at 37uC.A single wound was
created in the middle of each well using a micro-pipette tip. The
plate was incubated at 37uC at 5% CO2. The image of wound
closure was taken at different time courses. The relative migration
rate was expressed as relative width of the wounds/time. Three
independent experiments were performed in triplicate.
Transwell cell migration and invasion assay
Quantification of cell migration and invasion were performed
using QCMTM 24-Well Colorimetric Cell Migration Assay
(Millipore Corporation, Billerica, MA, USA) and Cell Invasion
Assay Kit (Chemicon International, Temecula, CA, USA)
according to the manufacturer’s instruction. Three different fields
of the stained cells were photographed and counted for each wells.
The experiments were performed three times independently.
In vivo tumor xenograft model
To investigate whether PITX2 overexpression promotes tumor
growth in vivo, PITX2 stably overexpressed SKOV-3 cells were
injected subcutaneously into nude mice. Diameter of the tumor
were measured every three days and the mice were scarified a
month after the injection. The tumor volume was calculated as
(mean of diameters)36p/6. All animal experiments were approved
by the University of Hong Kong Committee on the Use of Live
Animals in Teaching and Research (CULATR No. 2053-09).
Increased Expression of PITX2 in Ovarian Cancer
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37076
Data analysis
Data were presented as mean 6 SD. Student’s t-test was used to
analysis parametric data. A P-value of ,0.05 was considered
significant in all experiment.
Results
UpregulatedPITX2 is observed in ovarian cancer cells
Despite the functions of PITX2 during embryogenesis have
been extensively studied, the functional roles of PITX2 in human
cancers remain largely unknown. Here, we evaluated the
expression status of PITX2 in ovarian cancer samples (n = 97),
normal ovaries (n = 54), normal ovarian cell lines including two
HOSEs (HOSE 10-2 and HOSE 17-1) and one immortalized
human oviductal epithelial cell line (OE-E6/E7) by Q-PCR. We
found that PITX2 was significantly upregulated in ovarian cancer
samples (,15 folds) as compared with normal ovaries and ovarian
cell lines (P,0.001) (Figure 1A). Clinicopathological correlation
showed that the overexpressed PITX2 was remarkably associated
with high-grade (grade 3) (P=0.023) and clear cell subtype ovarian
cancer (P=0.011) (Table 1). However, there was no significant
association between the overexpressed PITX2 and other param-
eters such as age, stage and recurrence (Table 1). Besides, Western
blot analysis was also conducted to compare the expression of
PITX2 in a panel of human ovarian cancer cell lines and normal
ovarian surface epithelium (HOSEs) cells. Compared with HOSEs
cell lines, a widespread increase in PITX2 expression was observed
in all ovarian cancer cell lines (Figure 1B). In addition, our
Western blot data also showed that PITX2 was obviously
upregulated in a clear cell subtype ovarian cancer cell line
(TOV21G) when compared to OE-E6/E7 (Figure S1A), the
immortalized normal fallopian tube epithelial cell line. This result
further confirms the above clinicopathological findings. To further
evaluate the protein level of PITX2 in ovarian cancer samples,
immunohistochemical staining of PITX2 was performed in an
ovarian cancer tissue array (OVC481) which includes 16 cases of
ovarian cancer samples paired with normal ovaries. Consistent
with the Q-PCR findings, increased expression of PITX2 was
usually observed in ovarian cancer samples particularly in high-
grade or undifferentiated tumors as compared with their
corresponding uninvolved normal ovarian tissues (Figure S1B).
Furthermore, we examined the expression of PITX2 in a bigger
pool of ovarian cancer samples by using another commercial
ovarian cancer tissue array (OVC1021) which includes 2 normal,
2 benign, 1 borderline cystademoma and 97 malignant tumor
samples. Our finding showed that the upregulated PITX2 was
significantly correlated with high-grade ovarian tumor only
(P,0.001) and was consistent with the result of Q-PCR analysis
(Table 2).
PITX2 increases cell growth in ovarian cancer cells
Given that the upregulated PITX2 was associated with high-
grade ovarian cancer, PITX2 may possess oncogenic functions in
mediating aggressive phenotype in ovarian cancer cells. To test
this notion, we first generated PITX2 stable expressing clones
from two high-grade ovarian cancer cell lines (SKOV3 and
Figure 1. PITX2 is upregulated in ovarian cancer samples and cell lines. (A) Quantitative RT-PCR analysis was performed in normal ovaries
(n = 54) and ovarian cancer samples (n = 97) using PITX2 specific primer. 18S and TATA-box binding protein (TBP) were used as the internal loading
controls. *P,0.001. (B) Western blot analysis using anti-PITX2 antibody to evaluate the expression level of PITX2 (isoforms A, B and C)) (35 kDa) in
ovarian cancer cell lines (n = 9) and HOSE cell lines (n = 2). b-actin was used as a loading control. (C) Immunohistochemical analysis of PITX2
expression (nuclear staining) in borderline cystadenoma and high-grade (3) serous cystadenocarcinoma on an ovarian cancer tissue array (OVC1021).
Magnification: 206.
doi:10.1371/journal.pone.0037076.g001
Increased Expression of PITX2 in Ovarian Cancer
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37076
OVCA433) (Figure 2A). On the other hand, another high-grade
ovarian cancer cell lines with PITX2-high expression (OV2008),
as well as OVCA433 were chosen for stable knockdown of PITX2
using vector-based RNAi approach. Four shRNA constructs
targeting at different sites of PITX2 open-reading frame were
transiently transfected into the cells respectively and two of them
(K1 and K2) yielded 50–70% reduction of endogenous PITX2 was
chosen for stable transfection (Figure 2B). By XTT cell prolifer-
ation assay, the relative growth rate of the PITX2 stably
expressing clones in SKOV3 and OVCA433 cells was significantly
higher (1.5- to 3-fold) than their vector controls (Figure 2C). In
reverse, depletion of PITX2 in OV2008 and OVCA433 cells
significantly impaired their cell proliferation rate by 2- to 3-fold as
compared with their scrambled controls (Figure 2D).
Furthermore, enforced expression of PITX2 increased not only
the size but also the number of colonies in OVCA433 and
SKOV3 cells by 2-fold (P,0.05) and 8-fold (P,0.01) respectively
(Figure 3A). In contrast, depletion of PITX2 reduced both size and
number of colonies in OV2008 and OVCA433 cells by 2.6-fold to
5-fold (P,0.01) respectively as compared with their scrambled
control (Figure 3B). Collectively, these data suggest that the
upregulation of PITX2 could promote cell growth of ovarian
cancer cells and support the oncogenic roles of PITX2 in high-
grade ovarian tumor.
PITX2 enhances cell migration and invasion of ovarian
cancer cells
Previous studies have shown that PITX2 could trigger neuronal
cell migration during the development of mouse hypothalamus
[16], indicating that PITX2 possesses cell migratory promoting
capacity. Here, we attempted to investigate whether PITX2
confers a role in promoting cell migration and invasion of ovarian
cancer cells. We first conducted wound healing assay to examine
whether PITX2 could promote cell migration. Upon treatment of
Mitomycin C to exclude the factor of increased cell growth, we
observed that enforced expression of PITX2in SKOV3 cells
exhibited a faster wound closure rate than the vector control
(Figure 4A). Conversely, knockdown of endogenous PITX2 in
OVCA433 cells remarkably reduced the cell migration rate
observed in wound healing assay (P,0.05) (Figure 4B). Further-
more, by Transwell migration and invasion assays, we demon-
strated there were 2- to 3-fold (P,0.01)and 0.8- to 1.5-fold
(P=0.04 and 0.01) increase in cell migration rate and invasion rate
respectively in PITX2 stable expressing clones (C4 and C5) as
compared with the vector control of SKOV3 cells (Figure 4C). In
contrast, the numbers of cell penetrated through membrane in
Transwell migration assay and invaded through matrigel in
Transwell invasion assay were significantly reduced in PITX2
stable knockdown clones (K1 and K2) as compared with
scrambled control of OVCA433 (P,0.01) (Figure 4D). These
data suggest that PITX2 possesses capacity in promoting cell
migration and invasion in ovarian cancer cells.
PITX2 regulates Cyclin-D1 and C-myc in ovarian cancer
cells
Cyclin-D1 and C-myc are two crucial regulators in promoting
cell proliferation [17]. To address whether PITX2 regulates these
genes in promoting cell growth of ovarian cancer cells, we firstly
performed Q-PCR analysis and showed that there was 2–12 folds
increase in expressions of Cyclin-D1 and C-myc in PITX2 stably
expressing ovarian cancer cells (Figure 5A). Additionally, Western
blot analysis also revealed that both Cyclin-D1 and C-myc
elevated at least 60% in PITX2 stably expressing ovarian cancer
cells (Figure 5B). Conversely, knockdown of PITX2 remarkably
reduced the expressions of Cyclin-D1 and C-myc at least 20%
compared to their scrambled controls in OVCA 433 and OV2008
cells (Figure 5C).These findings indicate that PITX2 could
upregulate Cyclin-D1 and C-myc in promoting cell growth of
ovarian cancer cells.
PITX2 promotes in vivo tumor growth of ovarian cancer
cells
Apart from in vitro tumorigenic studies on PITX2, we attempted
to determine whether overexpression of PITX2 could enhance
tumor growth ability in a xenograft mouse model. Two PITX2
Table 1. PITX2 expression and clinicopathological co-relation
in ovarian cancer.
PITX2
expression level
Characteristics Total ,=3 folds .3 folds P-value
All cases 78 30(38.46%) 48(61.54%)
Age (y)
,50 42 16(38.1%) 26(61.9%)
§50 36 14(38.89%) 22(61.11%) 0.943
Stage
Early (T1+T2) 24 7(29.17%) 17(70.83%)
Late (T3) 53 23(43.40%) 30(56.6%) 0.236
Grade
Low (1&2) 27 16(59.26%) 11(40.74%)
High (3) 36 11(30.56%) 25(69.44%) 0.023*
Histology
clear cell 17 2(11.76%) 15(88.24%)
others 61 28(45.90%) 33(54.10%) 0.011*
Recurrance
+ 35 13(37.14%) 22(62.86%)
2 34 15(44.12%) 19(55.88%) 0.555
doi:10.1371/journal.pone.0037076.t001
Table 2. Clinicopathological analysis of PITX2 expression in
ovarian cancer tissue array (OVC1021, Pantomics, Inc.).
PITX2
expression
Characteristics Total ,=4 folds .4 folds P-value
All cases 97 32(33.0%) 65(67.0%)
Stage
Early (T1+T2) 73 21(28.8%) 52(71.2%)
Late (T3) 24 11(45.8%) 13(54.2%) 0.139
Grade
Low (1&2) 50 27(54.0%) 23(46.0%)
High (3) 46 4(8.7%) 42(91.3%) ,0.001*
Metastasis (Regional Lymph node+Distant)
Absence 73 21(28.8%) 11(71.2%)
Presence 24 11(45.8%) 13(54.2%) 0.139
doi:10.1371/journal.pone.0037076.t002
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stable expressing clones (C4 and C5) and a vector control of
SKOV3 were inoculated subcutaneously in nude mice. After 36
days, we observed that both stable clones with PITX2 overex-
pression had 2.5–3 fold increase intumor growth rate compared to
the vector control (P,0.01) (Figure 6A & 6B). Western blot
analysis on the dissected tumor tissues collected on Day 36 showed
that both PITX2 stable expressing clones (C4 and C5) of SKOV3
expressed high levels of PITX2 and concomitant with elevated
Figure 2. PITX2 promotes ovarian cancer cell growth. (A) PITX2A stable expressing clones were established in SKOV3 and OVCA433 cells.
Western blot analysis using anti-HA antibody showed the expression levels of HA-tagged PITX2A in C4 and C5 clones of SKOV-3, and C33 and C34
clones of OVCA 433. b-actin was used as loading control. (B) Western blot analysis using anti-PITX2 antibody showed the reduced expressions of
endogenous PITX2 in stable knockdown clones generated by 2 shRNA constructs (K1 and K2). Scrambled is the non-specific shRNA control. The
numerical units represent the relative expressions of PITX2 reduction in each stable clone as compared with the scrambled controls. b-actin was used
as loading control. (C) Ectopic expression of PITX2A stimulated cell proliferation in ovarian cancer cells. Both C4 and C5 of SKOV-3 cells demonstrated
1.5- fold increase of cell growth (* P,0.05), C33 and C34 of OVCA 433 cells had 3- fold increase of cell growth (** P,0.01) as compared with their
vector control. (D) Depletion of endogenous PITX2 reduced cell proliferation in ovarian cancer cells. A 3- to 4- fold of reduction on cell viability in
both knockdown clones (K1 and K2) of OV2008 cells (** P,0.01) and 2- to 3- fold decrease on cell proliferation in knockdown clones (K1 and K2) of
OVCA 433 cells (* P,0.05) were observed.
doi:10.1371/journal.pone.0037076.g002
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expressions of Cyclin-D1 and C-myc (Figure 6C). This result is
consistent with the in vitrotumorigenic data and further supports
that PITX2 could promote tumor growth through upregulation of
Cyclin-D1 and C-myc.
PITX2 is regulated by Wnt/b-catenin independently in
ovarian cancer cells
Previous reports have documented that PITX2 is the down-
stream mediator of Wnt/b-catenin pathway [12,18]. Therefore,
we were of interested to examine whether the upregulation of
PITX2 is due to the activated Wnt/b-catenin. Upon treatment of
GSK3b inhibitor (lithium chloride), we found that the Wnt/b-
catenin activity was activated through the increased expression of
b-catenin in a dose-dependent manner in OVCA433 and
A2780cp cells. However, there was only slight or even no change
of PITX2 expression in both cell lines (Figure S2A). Likewise,
upon treatment of Wnt3A condition medium, both A2780cp and
OVCA 433 cells showed unobvious response to the increased
Wnt/b-catenin activity (Figure S2B). These findings indicate that
the upregulation of PITX2 expression in ovarian cancer cells is not
mainly regulated by Wnt/b-catenin signaling but maybe by other
molecular mechanisms.
Figure 3. PITX2 enhances anchorage-independent growth ability of ovarian cancer cells. (A)Enforced expression of PITX2A enhanced
anchorage independent growth ability of ovarian cancer cells. The bar chart shows that PITX2A stably expressing clones (C33 and C34) of OVCA 433
(**P= 0.05) and (C4 and C5) of SKOV-3 (*P= 0.01) had increased number of colonies in soft agar compared with their vector controls. Representative
pictures show larger colony size in PITX2A stable expressing clones under microscopy. (B)Depletion of PITX2 by shRNA inhibited anchorage
independent growth ability of ovarian cancer cells. The number of colonies in PITX2stable knockdown clones (K1 and K2) of OVCA 433 and OV2008
showed significantly reduction as compared with the scrambled controls (* P,0.01). Representative pictures shows that the reduced colony size of
PITX2stableknockdown clones and their scrambled controls. The above experiment was repeated at least three times independently and the data
was calculated with mean 6 SD.
doi:10.1371/journal.pone.0037076.g003
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Figure 4. PITX2 promotes ovarian cancer cell migration and invasion. (A) Wound healing assay showed that PITX2 stably expressing cells
(C4 of SKOV-3) exhibited faster wound closure rate than the vector control in the time course of 8 hr (**P,0.05). (B) PITX2 stable knockdown clones
(K1 and K2 of OVCA 433) showed significant reduction on wound closure rate compared with vector control in the time course of 12 hrs (*P,0.05).
The arrows indicate the width of wound and the relative cell migration rate is expressed as relative width of the wounds/time. The assay was
repeated three times independently. (C) Transwell migration and invasion assay demonstrated that PITX2 stably expressing clones in SKOV3 (C4 and
C5) cells migrate faster through the membrane (*P,0.01) and invade faster through the matrigel (C4, *P= 0.04 and C5, **P=0.01) compared with the
vector control. (D) PITX2 stable knockdown clone (K2 of OVCA 433) exhibited remarkable reduction in cell penetration through the membranes and
cell invasiveness compared with the scrambled controls (**P= 0.01). Three views were randomly picked in each inserts and the numbers of invaded
cell were counted. The results of three independent experiments were plotted with error bar.
doi:10.1371/journal.pone.0037076.g004
Figure 5. PITX2 elevates the expressions of Cyclin-D1 and C-myc in ovarian cancer cells. (A) Q-PCR analysis revealed that the levels of
Cyclin-D1 and C-myc were elevated in PITX2A stably expressing clones (C4, C5 of SKOV-3 and C33, C34 of OVCA 433). (B)Western blot analysis showed
that the protein levels of Cyclin-D1 and C-myc were increased by PITX2 in PITX2A stably expressing clones (C4, C5 of SKOV-3 and C33, C34 of OVCA
433). (C) Knockdown of PITX2 significantly reduced the levels of Cyclin-D1 and C-myc in PITX2 knockdown stable clones (C6, C8 of OVCA 433 and C1,
C4 of OV2008). The levels of HA-tagged PITX2A were detected using anti-HA antibody, while endogenous PITX2 expression was examined by anti-
PITX2 antibody, b-actin was used as loading control. The numerical value under each panel represents the relative expression of Cyclin-D1 and C-myc
to their vector controls.
doi:10.1371/journal.pone.0037076.g005
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Discussion
Tumor progression is a multi-step process which advances
cancer to be a more malignant and aggressive phenotype [19].
High-grade tumor represents a more advanced progression which
possesses higher cell proliferative and invasiveness capacities [20].
In this study, we firstly demonstrated that PITX2 was frequently
upregulated in ovarian cancers particularly in high-grade and
clear cell subtype of ovarian cancer using Q-PCR, Western blot
and IHC analyses. More importantly, we addressed the oncogenic
role of PITX2 possesses in cell proliferation, anchorage-indepen-
dent growth ability, cell migration/invasion, as well as tumor
growth in a tumor xenograft mice model.
According to FIGO grading classification, high-grade ovarian
tumor cells are usually poorly histological differentiated [20], grow
faster and highly metastatic [7]. In addition, prognosis of high-
grade ovarian tumor is poor thereafter it often associates with poor
survival rate [21,22].The clear cell subtype ovarian cancer
accounts for approximately 6% of all epithelial ovarian tumors
and most cases of this subtype are high-grade tumor exhibiting an
aggressive phenotype [3,22,23]. Our study showed that both
mRNA and protein levels of PITX2 was frequently upregulated in
ovarian cancer particularly in the high-grade and clear cell
subtypes, indicating that PITX2may play an important role in
driving aggressive phenotypes in ovarian cancer.
PITX2 is a homeodomain transcription factor which plays an
essential role in embryonic development such as liver, hemato-
poiesis, gonads, and neuronal differentiation etc [24,25,26].
Recently, there have been increasing reports showing that PITX2
is overexpressed in human cancers such as nonfunctional pituitary
adenomas [10], Wilms tumor [27] and node-positive colorectal
cancer [11]. However, the functional roles of PITX2 in human
cancers such as ovarian cancer remain unknown. In order to
unveil the functional roles of PITX2 in ovarian cancer, we
generated gain or loss of function of PITX2 in high-grade ovarian
cancer cell models and performed a series of in vitro and in vivo
tumorigenic assays with regard to the effect of PITX2 in tumor cell
growth and metastasis. Our study demonstrated that enforced
expression of PITX2 could significantly enhance cell proliferation,
anchorage independent growth ability, cell migration/invasion
and tumor growth of ovarian cancer cells in mouse xenograft
tumor model. Conversely, depletion of PITX2 by shRNA
impaired the above tumorigenic phenotypes in high-grade ovarian
cancer cell models. Taken together, our findings suggest that the
oncogenic functions possessed by PITX2 are exclusively found in
high-grade ovarian cancer and are consistent with the clinico-
pathological analysis of that the overexpressed PITX2 is closely
correlated with high-grade ovarian cancer.
Previous studies have showed that PITX2 elevates cell cycle
regulatory factors such as Cyclin-D1, -D2 and C-myc promoting
cell-type specific proliferation in murine pituitary and myoblast
cell lines [18,28,29,30]. In addition, biochemical studies depicted
that PITX2 binding sites are located along the promoter regions of
Cyclin-D1, -D2 and C-myc, suggesting that these genes are direct
transcription targets of PITX2 [18,28,29,30,31,32]. Furthermore,
activation of oncogenes such as Cyclin-D1 and C-myc could
enhance anchorage-independent growth in mouse mammary
epithelial cells on and tumor growth in severe combined
immunodeficiency (SCID) mice [17]. These suggest that the
upregulation of Cyclin-D1 and C-myc contributes to more
aggressive features of tumors including metastasis. We thus
speculated that PITX2 enhanced cell proliferation, anchorage-
independent growth ability and in vivo tumor growth through
upregulation of these genes. As expected, our data clearly showed
that the expressions of both Cyclin-D1 and C-myc were
upregulated by PITX2even in tumor tissues obtained from tumor
xenograft mice, whereasPITX2 depleted ovarian cancer cells
exhibited reduction in the expressions of Cyclin-D1 and C-myc.
Collectively, these findings manifest PITX2 acts as a transcription
factor activating downstream oncogenes in mediating tumor
progression.
Previous studies have pointed out that PITX2 is one of the
downstream effectors of Wnt/b-catenin pathway [18,28,31].
However, our finding could not show any relationship between
Wnt/b-catenin signaling and PITX2 expression in ovarian cancer
cells. We showed that there was no significant change of PITX2
expression upon activation of Wnt/b-catenin activity in ovarian
cancer cell lines, suggesting that the aberrant upregulation of
PITX2 may be regulated in-dependently by canonical b-catenin
pathway in ovarian cancer cells. Therefore we speculated that the
upregulation of PITX2 in ovarian cancer might be due to other
genetics alterations. Further investigation in molecular mechanism
leading to PITX2 overexpression is warranted.
In conclusion, our findings suggest that PITX2 plays an
important role in ovarian cancer progression by promoting tumor
growth and migration/invasion in aggressive high-grade ovarian
cancer.
Supporting Information
Figure S1 (A) Western blot analysis showed the PITX2 was
upregulated in TOV21G clear cell subtype cell line as copared
Figure 6. PITX2 promotes the tumor growth in nude mice. (A)
PITX2 stably expressing clones in SKOV3 (C4 and C5) showed faster in
the tumor growth in nude mice as compared with the vector control.
The tumor size was represented by the mean6 SE of five mice and was
measured for 36 days.*, P,0.01, significantly different from vector
control group. (B) Photograph illustrates the dissected tumors taken
from nude mice subcutaneously injected by two PITX2 stable
expressing clones in SKOV3 (C4 and C5) and the vector control on
Day 36. (C) Western blot analysis showed the expressions of PITX2,
Cyclin-D1 and C-myc from the mice subcutaneous tumor tissues. The
numerical value under each panel represents the relative expression of
Cyclin-D1 and C-myc to their vector controls.
doi:10.1371/journal.pone.0037076.g006
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with an immortalized normal fallopian tube epithelial cell line OE-
E6/E7. (B) Immunohistochemical study on a commercial tissue
array 9OVC481, Pantomics) showed that increased expression of
PITX2 was observed in high-grade serous cystadenocarcinoma
and undifferentiated carcinoma as compared with their paired
uninvolved normal ovaries. Magnification: 206.
(TIF)
Figure S2 The expression of PITX2 is not altered by
Wnt/b-catenin activity in ovarian cancer cells. Western
blot analysis showed that activation of b-catenin either by (A)
Lithium chloride, or (B) treatment of Wnt3a media did not elevate
PITX2 levels in A2780cp and OVCA 433 cells. The numerical
value under each panel represents the relative expression of
PITX2 compared with the untreated control.
(TIF)
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